Tiglutik

E561111

Tiglutik is an oral suspension formulation of the ALS medication riluzole, designed to help slow disease progression in patients with amyotrophic lateral sclerosis.

All labels observed (1)

Label Occurrences
Tiglutik canonical 2

How this entity was disambiguated

Statements (28)

Predicate Object
instanceOf oral suspension ⓘ
pharmaceutical drug ⓘ
activeIngredient riluzole ⓘ
containsDosageForm oral liquid ⓘ
containsSubstance riluzole ⓘ
dosageForm oral suspension ⓘ
drugClass glutamate release inhibitor ⓘ
formulationType ready-to-use suspension ⓘ
hasAdministrationAdvantage facilitates dosing in patients with swallowing difficulties ⓘ
hasTradeName Tiglutik ⓘ
indication ALS ⓘ
amyotrophic lateral sclerosis ⓘ
indicationDetail treatment of patients with amyotrophic lateral sclerosis to extend survival or time to tracheostomy ⓘ
intendedUse management of ALS ⓘ
isFormulationOf riluzole ⓘ
mechanismOfAction inactivates voltage-dependent sodium channels ⓘ
inhibits glutamate release ⓘ
interferes with intracellular events following excitatory amino acid receptor activation ⓘ
pharmacologicalClass neuroprotective agent ⓘ
regulatoryStatus prescription only ⓘ
routeOfAdministration oral ⓘ
targetPopulation adult patients with ALS ⓘ
therapeuticArea neurodegenerative diseases ⓘ
neurology ⓘ
therapeuticEffect slows disease progression in ALS ⓘ
treatmentGoal prolong survival in ALS patients ⓘ
slow progression of ALS ⓘ
treatsSymptom functional decline in ALS ⓘ

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

Riluzole → hasBrandName → Tiglutik ⓘ
subject linked to: riluzole
Tiglutik → hasTradeName → Tiglutik ⓘ